Life Science Compliance Update



Swarming On The Opioid Crisis (Part 2): The DEA’s Quota System And Suspicious Order Monitoring Compliance Come Into Sharp Focus

Written by , Posted in Uncategorized

By Katherine Norris

This is the second article in the series exploring the major themes emerging from recent efforts to combat the ‘opioid crisis’ and their potential impact on drug manufacturers’ compliance programs. In this article, we explore the pressures facing the DEA to reduce diversion and the possibility of changes to the quota system.


  • Return to July 2018 LSC Update Table of Contents
  • Copy abstract URL
  • Order Reprints

  • Menu Title